

KAPPAC PHARMA LIMITED

CIN NO:L24230MH1981PLC025002

E mail: kappacpharma@yahoo.com

Date: 31.07.2018

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001
Scrip Code: 512017

Dear Sir/Madam,

Sub: Submission of Audited Financial Result for quarter ended 30th June, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone) of the Company for the quarter ended June 30, 2018 were approved by the Board of Directors of the Company at its meeting held today.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2018;
2. Limited Review Reports on the Unaudited Financial Results (Standalone) for the said quarter.

We request you to take the same on records.

Thanking you.

Yours faithfully,

FOR, KAPPAC PHARMA LIMITED



DIRECTOR / AUTHORIZED SIGNATORY

KAPPAC PHARMA LTD.

CIN:-L24230MH1981PLC025002

Regd. Office: 3/204, Mahajbeen Arched, Plot No. H-61, New Link Road, Opp Ashiwara Police Stn., Andheri (West), Mumbai - 400053

Email:- kappacpharma@yahoo.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2018

(Rs. In lacs)					
SI no.	Particulars	Quarter Ended 30 June 2018	Quarter Ended 31st March 2018	Quarter Ended 30 June 2017	Year Ended 31 Mar 2018
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	INCOME				
(a)	Revenue from Operations	-	-	-	-
(b)	Other Income	-	-	-	-
	Total Income	-	-	-	-
2	EXPENSES				
(a)	Cost of material consumed	-	-	-	-
(b)	Purchase of stock in trade	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	-	-	-	-
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-
(g)	Other expenses	0.12	0.03	0.26	0.69
	Total Expenses	0.12	0.03	0.26	0.69
3	Profit for the Period before Share of Profit / (Loss) of Associates And Joint Ventures	(0.12)	(0.03)	(0.26)	(0.69)
4	Share of Profit/ (Loss) of Associates & Joint Venture	-	-	-	-
5	Profit before tax	(0.12)	(0.03)	(0.26)	(0.69)
6	Tax Expense	-	-	-	-
7	Net Profit after taxes and Share of Profit/ (Loss) of Associates and Joint Ventures but before non-controlling interests	(0.12)	(0.03)	(0.26)	(0.69)
8	Non-controlling interests	-	-	-	-
9	Net Profit after taxes, non-controlling interests and share of profit / (loss) of Associates and Joint Ventures	(0.12)	(0.03)	(0.26)	(0.69)
10	Other comprehensive income				
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or loss	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-
11	Total comprehensive income (9+10)	(0.12)	(0.03)	(0.26)	(0.69)
14	Paid-up equity share capital (Face Value of Rs.10/- each)	3,026.50	3,026.50	3,026.50	3,026.50
15	Other Equity				769.28
16	Earnings Per Share (of Rs. 10/- each) (not annualised):				
	(a) Basic	(0.00)	(0.00)	(0.00)	(0.00)
	(b) Diluted	(0.00)	(0.00)	(0.00)	(0.00)

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 31, 2018. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Mumbai

Date : 31st July, 2018

By order of the Board

Director





RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, 26419136, Email : rishisekhri@gmail.com

Limited Review Report

To
The Board of Directors of
KAPPAC PHARMA LTD.

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of KAPPAC PHARMA LTD. ("the Company"), for the Quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RISHI SEKHRI AND ASSOCIATES.
Chartered Accountants
FRNo.: 128216W

(CA RISHI SEKHRI)

Partner

MEMBERSHIP No.: 126656

Place: Mumbai
Date: 31.07.2018

